Smoking cessation and outcome after ischemic stroke or TIA

IRIS Trial Investigators, Giancarlo Comi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking. METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized to pioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the differences in stroke, MI, and death after 4.8 years, with correction for adjustment variables prespecified in the IRIS trial: age, sex, stroke (vs TIA) as index event, history of stroke, history of hypertension, history of coronary artery disease, and systolic and diastolic blood pressures. RESULTS: At the time of their index event, 1,072 (28%) patients were current smokers. By the time of randomization, 450 (42%) patients had quit smoking. Among quitters, the 5-year risk of stroke, MI, or death was 15.7% compared to 22.6% for patients who continued to smoke (adjusted hazard ratio 0.66, 95% confidence interval 0.48-0.90). CONCLUSION: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort. © 2017 American Academy of Neurology.
Original languageEnglish
Pages (from-to)1723-1729
Number of pages7
JournalNeurology
Volume89
Issue number16
DOIs
Publication statusPublished - 2017

Fingerprint

Smoking Cessation
Stroke
Insulin Resistance
pioglitazone
Smoking
Myocardial Infarction
Blood Pressure
Social Adjustment
Tobacco Use
Insurance Benefits
Random Allocation
Proportional Hazards Models
Smoke
Observational Studies
Coronary Artery Disease
Cohort Studies
History
Placebos
Confidence Intervals
Interviews

Cite this

Smoking cessation and outcome after ischemic stroke or TIA. / IRIS Trial Investigators ; Comi, Giancarlo.

In: Neurology, Vol. 89, No. 16, 2017, p. 1723-1729.

Research output: Contribution to journalArticle

IRIS Trial Investigators ; Comi, Giancarlo. / Smoking cessation and outcome after ischemic stroke or TIA. In: Neurology. 2017 ; Vol. 89, No. 16. pp. 1723-1729.
@article{536e34e15be6441a9f1f13b3dd171e18,
title = "Smoking cessation and outcome after ischemic stroke or TIA",
abstract = "OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking. METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized to pioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the differences in stroke, MI, and death after 4.8 years, with correction for adjustment variables prespecified in the IRIS trial: age, sex, stroke (vs TIA) as index event, history of stroke, history of hypertension, history of coronary artery disease, and systolic and diastolic blood pressures. RESULTS: At the time of their index event, 1,072 (28{\%}) patients were current smokers. By the time of randomization, 450 (42{\%}) patients had quit smoking. Among quitters, the 5-year risk of stroke, MI, or death was 15.7{\%} compared to 22.6{\%} for patients who continued to smoke (adjusted hazard ratio 0.66, 95{\%} confidence interval 0.48-0.90). CONCLUSION: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort. {\circledC} 2017 American Academy of Neurology.",
author = "KA Epstein and CM Viscoli and JD Spence and LH Young and SE Inzucchi and M Gorman and B Gerstenhaber and Guarino, {Peter D} and A Dixit and KL Furie and WN Kernan and {IRIS Trial Investigators} and Giancarlo Comi",
note = "Comi, G in appendice",
year = "2017",
doi = "10.1212/WNL.0000000000004524",
language = "English",
volume = "89",
pages = "1723--1729",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "16",

}

TY - JOUR

T1 - Smoking cessation and outcome after ischemic stroke or TIA

AU - Epstein, KA

AU - Viscoli, CM

AU - Spence, JD

AU - Young, LH

AU - Inzucchi, SE

AU - Gorman, M

AU - Gerstenhaber, B

AU - Guarino, Peter D

AU - Dixit, A

AU - Furie, KL

AU - Kernan, WN

AU - IRIS Trial Investigators

AU - Comi, Giancarlo

N1 - Comi, G in appendice

PY - 2017

Y1 - 2017

N2 - OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking. METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized to pioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the differences in stroke, MI, and death after 4.8 years, with correction for adjustment variables prespecified in the IRIS trial: age, sex, stroke (vs TIA) as index event, history of stroke, history of hypertension, history of coronary artery disease, and systolic and diastolic blood pressures. RESULTS: At the time of their index event, 1,072 (28%) patients were current smokers. By the time of randomization, 450 (42%) patients had quit smoking. Among quitters, the 5-year risk of stroke, MI, or death was 15.7% compared to 22.6% for patients who continued to smoke (adjusted hazard ratio 0.66, 95% confidence interval 0.48-0.90). CONCLUSION: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort. © 2017 American Academy of Neurology.

AB - OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking. METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized to pioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the differences in stroke, MI, and death after 4.8 years, with correction for adjustment variables prespecified in the IRIS trial: age, sex, stroke (vs TIA) as index event, history of stroke, history of hypertension, history of coronary artery disease, and systolic and diastolic blood pressures. RESULTS: At the time of their index event, 1,072 (28%) patients were current smokers. By the time of randomization, 450 (42%) patients had quit smoking. Among quitters, the 5-year risk of stroke, MI, or death was 15.7% compared to 22.6% for patients who continued to smoke (adjusted hazard ratio 0.66, 95% confidence interval 0.48-0.90). CONCLUSION: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort. © 2017 American Academy of Neurology.

U2 - 10.1212/WNL.0000000000004524

DO - 10.1212/WNL.0000000000004524

M3 - Article

VL - 89

SP - 1723

EP - 1729

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 16

ER -